LEADER 03625nam  22005775  450 
001 9910298438603321
005 20200706155217.0
010   $a3-319-73238-2
024 7 $a10.1007/978-3-319-73238-1
035   $a(CKB)4100000003359275
035   $a(MiAaPQ)EBC5372066
035   $a(DE-He213)978-3-319-73238-1
035   $a(PPN)226698580
035   $a(EXLCZ)994100000003359275
100   $a20180425d2018      u|             0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAccelerated Path to Cures$b[electronic resource] /$fedited by Josep Bassaganya-Riera
205   $a1st ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018.
215   $a1 online resource (88 pages)
311   $a3-319-73237-4 
327   $aChapter 1: Introduction to Accelerated Path to Cures and Precision Medicine in Inflammatory Bowel Disease -- Chapter 2: Computer-Aided Drug Discovery -- Chapter 3: Preclinical Studies: Efficacy and Safety -- Chapter 4: From Nutritional Immunology to Drug Development -- Chapter 5: Development of Synthetic Patient Populations and In Silico Clinical Trials.
330   $aAccelerated Path to Cures provides a transformative perspective on the power of combining advanced computational technologies, modeling, bioinformatics and machine learning approaches with nonclinical and clinical experimentation to accelerate drug development. This book discusses the application of advanced modeling technologies, from target identification and validation to nonclinical studies in animals to Phase 1-3 human clinical trials and post-approval monitoring, as alternative models of drug development. As a case of successful integration of computational modeling and drug development, we discuss the development of oral small molecule therapeutics for inflammatory bowel disease, from the application of docking studies to screening new chemical entities to the development of next-generation in silico human clinical trials from large-scale clinical data. Additionally, this book illustrates how modeling techniques, machine learning, and informatics can be utilized effectively at each stage of drug development to advance the progress towards predictive, preventive, personalized, precision medicine, and thus provide a successful framework for Path to Cures. .
606   $aImmunology
606   $aBioinformatics
606   $aHealth informatics
606   $aBioinformatics 
606   $aComputational biology 
606   $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000
606   $aComputational Biology/Bioinformatics$3https://scigraph.springernature.com/ontologies/product-market-codes/I23050
606   $aHealth Informatics$3https://scigraph.springernature.com/ontologies/product-market-codes/I23060
606   $aComputer Appl. in Life Sciences$3https://scigraph.springernature.com/ontologies/product-market-codes/L17004
615  0$aImmunology.
615  0$aBioinformatics.
615  0$aHealth informatics.
615  0$aBioinformatics .
615  0$aComputational biology .
615 14$aImmunology.
615 24$aComputational Biology/Bioinformatics.
615 24$aHealth Informatics.
615 24$aComputer Appl. in Life Sciences.
676   $a615.190285
702   $aBassaganya-Riera$b Josep$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910298438603321
996   $aAccelerated Path to Cures$92544113
997   $aUNINA